About the Company
We do not have any company description for Immunovant, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMVT News
What Makes Immunovant (IMVT) a New Buy Stock
Investors might want to bet on Immunovant, Inc. (IMVT), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
Here's Why Immunovant, Inc. (IMVT) is Poised for a Turnaround After Losing -8.02% in 4 Weeks
A downtrend has been apparent in Immunovant, Inc. (IMVT) lately with too much selling pressure. The stock has declined 8% over the past four weeks. However, given the fact that it is now in ...
Immunovant is Now Oversold (IMVT)
A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Immunovant Inc (Symbol: IMVT) entered into oversold territory, hitting an RSI reading of 29. ...
Immunovant (IMVT) Up on Upbeat Initial Batoclimab GD Study Data
Immunovant, Inc. IMVT announced top-line results from the initial cohort of patients in an ongoing 24-week phase II study of batoclimab in patients with Graves’ disease (GD), observing more than ...
Immunovant Inc IMVT
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Immunovant Stock (NASDAQ:IMVT), Analyst Ratings, Price Targets, Predictions
Immunovant Inc has a consensus price target of $39, established from looking at the 59 latest analyst ratings. The last 3 analyst ratings were released from Oppenheimer, Truist Securities ...
Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials
Begin your TipRanks Premium journey today. Immunovant (IMVT) Company Description: Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients ...
Immunovant Awarded U.S. Patent for IMVT-1402
Composition of matter patent issued with coverage until June 2043 Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. ...
Immunovant Stock (NASDAQ:IMVT), Quotes and News Summary
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following ...
Immunovant gets grant for anti-FCRN antibody with improved stability for autoimmune disease treatment
Discover Immunovant Inc's groundbreaking patent for an anti-FcRn antibody, a game-changer in autoimmune disease treatment. Learn about its stability, efficacy, and potential impact on patient outcomes ...
Why Is Immunovant, Inc. (IMVT) Down 14.7% Since Last Earnings Report?
It has been about a month since the last earnings report for Immunovant, Inc. (IMVT). Shares have lost about 14.7% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Loading the latest forecasts...